(51) International Patent Classification 6: A61K 38/11

(11) International Publication Number: WO 98/43660

(43) International Publication Date: 8 October 1998 (08.10.98)

(21) International Application Number: PCT/SE98/00553

(22) International Filing Date: 26 March 1998 (26.03.98)

(30) Priority Data: 9701161–3 27 March 1997 (27.03.97) SE


(72) Inventors: and


(74) Agents: LARFELDT, Helene et al.; Bergenstråhle & Lindvall AB, P.O. Box 17704, S–118 93 Stockholm (SE).


Published
With international search report.

(54) Title: USE OF SUBSTANCES HAVING OXYTOCIN ACTIVITY FOR PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF AFFECTIVE PAIN SYNDROMES

(57) Abstract

Substances having oxytocin activity can be used for the preparation of a pharmaceutical composition for treatment or prophylaxis of affective pain syndromes, such as fibromyalgia and navel colic. The pain relieving effect can be strengthened or prolonged by combining oxytocin with oestrogen.
### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
<td>LS</td>
<td>Lesotho</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GE</td>
<td>Georgia</td>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslav</td>
</tr>
<tr>
<td>BF</td>
<td>Burundi</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>MB</td>
<td>Mauritania</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>KP</td>
<td>Democratic People’s Republic of Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KC</td>
<td>Kazakhstan</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KC</td>
<td>Kazakhstan</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td></td>
<td></td>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>SI</td>
<td>Slovenia</td>
<td>SK</td>
<td>Slovakia</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>SZ</td>
<td>Swaziland</td>
<td>TD</td>
<td>Chad</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>TJ</td>
<td>Tajikistan</td>
<td>TM</td>
<td>Turkmenistan</td>
<td>TR</td>
<td>Turkey</td>
</tr>
<tr>
<td>TT</td>
<td>Trinidad and Tobago</td>
<td>UA</td>
<td>Ukraine</td>
<td>UG</td>
<td>Uganda</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
<td></td>
<td></td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>UZ</td>
<td>Uzbekistan</td>
<td>VN</td>
<td>Viet Nam</td>
<td>YU</td>
<td>Yugoslavia</td>
</tr>
<tr>
<td>ZW</td>
<td>Zimbabwe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The present invention refers to a new use of oxytocin.

5 **Background of the invention**

Pain syndromes which have no readily identifiable cause are characterized by chronic pain for which no abnormality can be demonstrated either in histological sections or in the physiology of the affected tissues. Fibromyalgia syndrome and myofascial pain syndrome are two such complex conditions for which there is still no useful treatment. Other pain syndromes of non organic origin are recurrent abdominal pain in children and different types of colic or irritable bowel syndrome.

Fibromyalgia syndrome is a common clinical pain disorder in which palpable fibrositic tender points, FTP, are associated with generalised muscular aching, morning stiffness, fatigue and nonrestorative sleep. Widespread pain which can be described as chronic muscular aching in all parts of the body is the dominating feature of the disease and the presence of FTP distinguishes from other diseases in the category soft tissue rheumatism. Many of the patients also present more or less serious irritable bowel syndromes. Fibromyalgia mainly affects women between 40 and 45 years of age.

The pathophysiology of fibromyalgia is unknown. Theories about its aetiology fall into four main categories, that is sleep disturbances, muscle abnormalities, neuropeptide changes and immune system alterations. It is commonly believed that the microcirculation is impaired in patients with fibromyalgia. It has been suggested that the chronic pain and point tenderness can be ascribed to a disorder of the pain-sensing pathways in the nervous system. Serotonin, that is 5-hydroxytryptamine, and noradrenaline are central nervous system neurotransmitters which might be involved in the generation or maintaining of fibromyalgia.

Drug therapy alone is often insufficient for patients with fibromyalgia. Analgesics and antiinflammatory agents do not give any relief. There are, however, completed clinical
trials showing that some antidepressants, such as amitriptyline and cyclobenzaprine, can be effective in at least a minor group of patients. A disadvantage with even low doses of these drugs are that they are often poorly tolerated; common side-effects are drowsiness, agitation and gastrointestinal upset. There are also other antidepressants, that is serotonin receptor antagonists which have no or little effect on the symptoms and signs of fibromyalgia. Alprazolam, a triazolobenzodiazepine, approved for the treatment of anxiety and depression, gave together with ibuprofen a significant greater than 30 % improvement in half of the patients. The drop out rate was greater than expected and the improvements were slow to occur, for some patients 16 weeks of treatment were required. Cognitive behavioural therapy in conjunction with aerobic exercise, physiotherapy, biofeedback training and relaxation therapy may be of benefit at least to selected patients, but will not constitute a solution. (Wall, P.D., Melzack, R., eds, Pain, Churchill Livingstone, 1995, McCain, G.A., Fibromyalgia and myofascial pain syndromes.)

Navel colic or recurrent abdominal pain of non-organic origin, RAP, is a common, probably psychosomatic disorder of childhood, which causes much distress due to pain, worry and social inhibition. The diagnostic criteria are vague and based more on exclusion than on positive clinical and laboratory signs. The classical definition of RAP, as given by Apley J. (The child with abdominal pains, Oxford, Blackwell, 1975), is as follows: "A period of three or more episodes of abdominal pain occurring over a period of at least 3 months, affecting the child's activities, yet where no sign of organic disease is found".

Today the general opinion is that RAP has a psychosomatic origin, that is bodily symptoms of psychic, emotional or mental origin. There are however no clear-cut answers. Life events, stress and depression play a part but seem to explain only some of the causes of RAP.

The most prominent feature of this disorder is, as its name implies, recurrent abdominal pains, which may vary in intensity between mild and intense pain, in duration between a few seconds and whole days, and in frequency between less
than one attack per month and several attacks per day. The pain focuses mainly around the umbilicus. Also other pains, such as headache, limb pains and chest pains are common among RAP children. Gastrointestinal symptoms are also very common, such as loss of appetite, nausea, vomiting, obstipation and mild diarrhea. It has been demonstrated that children with recurrent abdominal pain have tense and tender abdominal wall muscles, especially around the navel, owing to an increased muscular tension (Acta Paediatr. 1993; 82: 400-3, Alfvén G., Preliminary findings on increased muscle tension and tenderness, and recurrent abdominal pain in children. A clinical study). Traits such as introversion and susceptibility to anxiety may be common among RAP children. The complex clinical picture including endocrinological deviances, as well as muscular symptoms points to a psychosomatic origin.

There are different types of colic, some of which do not respond to analgesics or opioids. Said colic conditions can be described as a cramp and pain condition in the colon, which e.g. are caused by the formation of gas and accompanying expansion of the intestines, resulting in muscular cramp and dysfunction. Infant colic is one such condition. Irritable bowel syndrome, IBS, or RAP in adulthood is a related condition referring to a complex of symptoms from the gastrointestinal tract, such as bowel pain, disordered defecation habits and flatus.

There are several different types of pain. In case of a tissue damage or lesion, pain receptors, so called nociceptors, are activated by mechanical, thermal or chemical stimuli. The information is transported through nerves, the spinal cord and the brain stem to the brain cortex where the pain is experienced. Pain can also arise anywhere in the pain pathway or by damage to the control systems affecting the transmission of the pain signals in the cord or in the ascending systems, that is the brain stem and the thalamus. From the thalamus impulses are led to the sensoric area of cortex, as well as to the limbic system, the part of the brain that controls emotional reactions. Pain is generally divided into four different types, that is nociceptive, neurogenic, idiopathic and psychogenic (Arnér, S., Differentia-
tion of pain and treatment efficacy, Thesis Karolinska
Institutet, Stockholm, Sweden, 1991). A nociceptive pain is
caused by tissue damage, a neurogenic pain by a damage or
malfuction of the nervous system, a psychogenic pain by a
psychic disorder or disturbance, and the origin of idiopathic
pain is still unknown.

It is well known that pain except its classification
into nociceptive, neurogenic, idiopathic and psychogenic pain
also may be classified by its two main components: sensory
and affective (Price, DD, et al., Pain 17:45-56, 1983). The
sensory component deals with the intensity of the perceived
pain and is projected on the gyrus cinguli, thalamus-and the
somatosensory cortex and. The affective component on the
other hand refers to the perception of pain and is projected
in amygdala, hippocampus, hypothalamus, locus ceruleus (LC)
and nucleus tractus solitarius (NTS) and accompanied by
activity in the frontal cortex, the so called associative
cortex. The sensory component of pain may be studied by
reflex methodology as used in the study by Kurosawa et al.,
Regulatory Peptides, 1998 (in press). It is important to
stress that drugs affecting the sensory component, e.g. local
anaesthetics, NSAIDs etc may leave the affective component
unaltered/unchanged and vice versa. In an experimental study
on the effects of oxytocin on the sensory aspects of IBS pain
it is demonstrated that it prolongs the withdrawal latencies,
a finding interpreted as modulation of nociception. This
finding of changes in reflex responses is of theoretical
interest, but has no relevance to the finding of reduced pain
(affective component) reported in our patent. Experimental
studies using PET have demonstrated that the pain associated
with IBS is projected to the frontal cortex, i.e. being
mainly of an affective nature. To elucidate if oxytocin has
any influence on the central sensory components of pain,
studies using somatosensory evoked potentials (SEP) were
carried out in rats. Nociceptive stimulation was applied to
the skin, muscle and viscera and the evoked potentials
recorded. Oxytocin was then administered either sub-
cutaneously, intravenously or intrathecally in doses pre-
viously shown to relieve nociceptive behaviour. The
administration of oxytocin did not effect the SEPs, i.e. oxytocin has no effect on the central projections of the sensory component of pain. Taken together our results are the first to demonstrate that oxytocin affects the affective component of pain, the component being of relevance in fibromyalgia and IBS (Ward et al., Pain 7:331-349, 1979).

Furthermore, it has been demonstrated that the affective component of pain is related to anxiety and depression. This is of particular interest as we have found that oxytocin as well as sedatives and antidepressants induces anxiolysis utilizing similar mechanisms. The two latter also being used for the alleviation of fibromyalgia and IBS.

As it previously has been reported that the expression of oxytocin receptors is influenced (increased) by estrogen, female rats were treated with a combination of estrogen and oxytocin and the anxiolytic effect was investigated. The results show that this combination potentiated the anxiolytic effects. In two female patients with fibromyalgia obtaining minor relief with i.n. administration of oxytocin, estrogen supplementation was added. Both patients reported a more marked alleviation of their pain.

It has recently been shown that vagal and sympathetic afferent nerves also may contribute to the sensation of pain and illness behaviour such as anxiety, muscle soreness, sleep disturbances etc. This could be an indication of that the vagal and/or sympathetic pathway may contribute to pain in the above mentioned pain syndromes. This would also explain why previously used treatments, such as with opioids, NSAIDs etc are ineffective.

There are several mechanisms in the human body for the reduction of pain, for instance the ability to produce endorphines. Certain transmitter substances of importance in psychic depression, especially serotonin, also have an influence on the sensitivity of the pain pathway. Treatment with analgesics is effective to reduce pain caused by injury, for instance a fracture or inflammation. Said substances, however, have no effect on neurogenic or psychogenic pain for which antidepressive drugs sometimes might have a pain reducing effect, nor an effect on idiopathic pain. It is also
well known that patients suffering from idiopathic pain do not respond to opioids.

Today there is no treatment available resulting in a complete relief of idiopathic pain in the conditions described above.

Prior art

Samborski et al., Biochemische Veränderungen bei der Fibromyalgie, Z Rheumatol, 1996: 55(3), 168-73 reports that patients with fibromyalgia revealed a significantly decreased level of e.g. serotonin and a significantly increased level of prolactin in blood. For oxytocin no significant difference could be observed.

Children with recurrent abdominal pain of non-organic origin have been shown to have reduced concentrations of oxytocin and cortisol in plasma, but no significant difference in prolactin level compared to a group of control children; Alfvén G., de la Torre B., Uvnäs Moberg K., Depressed plasma concentrations of cortisol and oxytocin in children with recurrent abdominal pain of non-organic origin Acta Paediatr., 83(10), 1076-80, 1994.

An anti-nociceptive effect of oxytocin has been demonstrated in rats after s.c. administration, which effect can be reversed by the opioid antagonist naloxone; Petersson et al., Oxytocin increases nociceptive thresholds in a long-term perspective in female and male rats, Neuroscience Letters 212, 87-90, 1996. It is suggested that oxytocin increases the synthesis and release of endogenous opioids and might be used as an analgesic. Pain-relieving effects have also been shown in humans in patients with low back pain and in patients with cancer pain. The type of pain concerned in these cases obviously is a nociceptive and/or neurogenic pain and there is nothing indicating that oxytocin could have an effect also on idiopathic pain. It is important to stress that pain has many different causes which explains why different treatments may have a pain relieving effect. Nociceptive pains like low back pain and cancer pain respond to opioids. Low back pain and cancer pain of neurogenic origin have been shown to respond to opioids but to a lesser degree.
Oxytocin was one of the first peptide hormones to be isolated and sequenced. It is a nonapeptide with two cysteine residues that form a disulfide bridge between positions 1 and 6 and corresponds to the formula

\[ \text{Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-GlyNH}_2 \]

For a long time the only effects attributed to oxytocin were its stimulating effects on milk ejection and uterine contractions, but in the past decades it has been shown that oxytocin exerts a wide spectrum of effects within the CNS. It has been suggested that oxytocin participates in the control of memory and learning processes and of various types of behaviour such as feeding, locomotion, as well as maternal and sexual behaviour. Oxytocin is also suggested to participate in the control of cardiovascular functions, thermoregulation, pain threshold and fluid balance. There is also evidence that oxytocin is involved in the control of various immunological processes. It has recently been demonstrated that oxytocin injections cause a lowering of blood pressure and increased weight gain long-lasting effects after repetitive administration.

**Description of the invention**

It has now surprisingly been found that substances with oxytocin activity have a pain relieving effect in patients suffering from an affective pain syndrome. As it is well known that affective pain is not alleviated by opioids the obtained effect was highly unexpected and implicates that said pain relief is mediated by other factors.

Idiopathic pain, such as in fibromyalgia, has for a long time been considered to be one of the most therapeutic resistant forms of pain. The effects obtained with oxytocin are surprising also because all other forms of interventions tried have proven to be either ineffective or to have only a limited effect in a limited number of patients.

The invention refers to the use of substances with oxytocin activity for the preparation of a pharmaceutical
composition for treatment or prophylaxis of affective pain syndromes of non-organic origin, such as fibromyalgia, myofascial pain syndrome, navel colic, colitis or irritable bowel syndrome, and affective components associated with pain of organic origin in mammals including man.

A preferred use of the invention is for the treatment of fibromyalgia.

Another preferred used is for the treatment of navel colic.

There are different processes described for the synthetic production of oxytocin; commercial processes are for instance described in US patents 2,938,891 and 3,076,797.

In the human body oxytocin is produced in the paraventricular nucleus, PVN, and the supraoptic nucleus, SON, of the hypothalamus. It differs by only two amino acids from vasopressin, which is also produced in these nuclei. The magnocellular oxytocinergic neurons of the SON and PVN send projections into the posterior pituitary gland from which oxytocin or vasopressin are secreted into the circulation.

Parvocellular neurons that originate in the PVN project into multiple areas within the central nervous system, CNS. The oxytocin-producing cells are innervated by cholinergic, catecholaminergic as well as peptidergic neurons. The presence of oxytocin in different tissues outside the brain, such as the uterus, ovaries, testis, thymus, adrenal medulla and pancreas has been demonstrated and oxytocin is suggested to exert local effects in these organs.

A parallel secretion of oxytocin into the brain regions and into the circulation occurs in response to some stimuli such as suckling, but other stimuli may cause separate activation of oxytocinergic neurons, terminating in the brain or the pituitary.

In this context oxytocin refers, whenever applicable, in addition to oxytocin also to precursors, metabolic derivatives, oxytocin agonists or analogues displaying the same properties.

Substances with oxytocin activity according to the invention can be described by the general formula I
wherein

- **W** is selected from the group consisting of Ile, Cha, Val, Hoph and Phe;
- **X** is selected from the group consisting of Gln, Ser, Thr, Cit, Daba and Arg;
- **Y** is selected from the group consisting of Leu, Ile, Arg, Hos, Daba, Cit and Val; where Leu, Ile and Val give oxytocin analogues and Arg, Hos, Daba and Cit give vasopressin analogues; and
- **Z** is selected from the group consisting of Gly and Ala.

The unnatural amino acids in said substances have the following structures:

- **Cha** (cyclohexylalanine)

- **Hoph** (homophenylalanine)

- **Cit** (citrulline)

- **Daba** (diphenylbuturic acid)

- **Hos** (homoserine)
Said amino acids are all commercially available, for instance from Bachem and Sigma.

The amino acids in the substances according to the invention can be either L- or D-amino acids.

Substances according to the invention also include nonapeptides having sequences with reversed peptide bonds. These sequences are preferably inverted sequences; more preferably comprising D-amino acids.

The nonapeptides of the formula I are believed to present oxytocin activity owing to the structural similarity to oxytocin having the formula:

\[
\text{Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH}_2
\]

In the oxytocin structure the positions 1, 2, 5, 6 and 7 have remained unchanged, that is the disulfide bridge, and the amino acids believed to stabilize said bridge and to be of critical importance for the properties, that is Tyr in position 2, Asn in position 5 and Pro in position 7. In position 3 the hydrophobic Ile can be exchanged for other hydrophobic amino acids and in position 4 the hydrophilic Gln can be exchanged for other hydrophilic amino acids. In position 8 oxytocin analogues are obtained if Leu is exchanged for the hydrophobic amino acids Ile or Val, and vasopressin analogues are obtained if exchanged for the hydrophilic amino acids Arg, His, Cit or Daba. The nonapeptides of the invention have been compiled through methods described by S. Hellberg et al., "Peptide Quantitative Structure-Activity Relationships, a multivariate approach", J. Med. Chem. 1987, 30, 1126 and J. Jonsson et al., "Multivariate parametrization of 55 coded and non-coded amino acids" Quant. Struct.-Act. Relat., 8. 204-209 (1989). The peptides can be synthesised according to known methods (e.g. Merrifields solid phase synthesis for instance as described in Streitwieser and Heathcock, Introduction to Organic Chemistry 3rd ed, p 949-950.) Sequences with reversed peptide bonds can also be prepared through e.g retro-inverso-modification (see e.g. S. Müller et al, PNAS vol 94 nov 97,
The use of oxytocin constitutes a preferred embodiment of the invention. Another preferred embodiment of the invention is the use of the substances mesotocin, isotocin, vasopressin or vasotocin having the formulas:

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Ile-Gly-NH$_2$ (mesotocin) (when in formula I W=Ile, X=Gln, Y=Ile and Z=Gly)

Cys-Tyr-Ile-Ser-Asn-Cys-Pro-Ile-Gly-NH$_2$ (isotocin) (when in formula I W=Ile, X=Ser, Y=Ile and Z=Gly)

Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH$_2$ (vasopressin) (when in formula I W=Phe, X=Gln, Y=Arg and Z=Gly)

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH$_2$ (vasotocin) (when in formula I W=Ile, X=Gln, Y=Arg and Z=Gly)

Other preferred substances for use according to the invention are:

Cys-Tyr-Cha-Cit-Asn-Cys-Pro-Arg-Gly-NH$_2$,

Cys-Tyr-Val-Thr-Asn-Cys-Pro-Leu-Gly-NH$_2$,

Cys-Tyr-Hoph-Thr-Asn-Cys-Pro-Val-Gly-NH$_2$,

Cys-Tyr-Phe-Cit-Asn-Cys-Pro-Leu-Gly-NH$_2$,

Cys-Tyr-Cha-Arg-Asn-Cys-Pro-Hos-Ala-NH$_2$,

Cys-Tyr-Val-Daba-Asn-Cys-Pro-Daba-Ala-NH$_2$,

Cys-Tyr-Hoph-Daba-Asn-Cys-Pro-Cit-Ala-NH$_2$ and

Cys-Tyr-Phe-Arg-Asn-Cys-Pro-Val-Ala-NH$_2$.

In experiments, which are described below, it has been
shown that oxytocin by way of a central action increases the activity of the central $\alpha_2$-receptors in rats. These receptors have an inhibitory action and counteracts the activating aspects of noradrenalin in the brain which are mainly mediated via $\alpha_1$-receptors, which activate cyclic AMP. When $\alpha_2$-receptor stimulation dominates over $\alpha_1$-receptor stimulation, activity is exchanged by relaxation and energy is shunted towards growing and healing, i.e. is not used for stress or muscular contraction and activity. As a consequence parasympathetic nerve tone dominates over sympathetic nervous tone and the musculature is relaxed. It can be presumed that oxytocin exerts a similar effect also in humans. During breast feeding - a situation characterized by repetitive oxytocin secretion - all the effects observed in experimental animals following repeated oxytocin administration are seen. It is not known how the effect by oxytocin on the $\alpha_2$-receptors is mediated, but probably not by a classical oxytocin receptor mediated effect.

The effect of oxytocin can be extended or strengthened by administration in combination with drugs increasing the release of oxytocin and/or the number of receptors, such as estrogen, or drugs having an $\alpha_2$-agonistic effect, such as clonidine.

The invention also refers to the use of oxytocin in combination with estrogen for the preparation of a pharmaceutical composition for the curative or prophylactic treatment of muscoskeletal pain syndromes of non-organic origin, especially for the treatment of fibromyalgia. Oxytocin and estrogen are either administrated together or estrogen is given first and oxytocin subsequently. Estrogen increases release and synthesis of oxytocin, the synthesis of oxytocin receptors, and it also upregulates the activity of $\alpha_2$-receptors.

The short term effects of oxytocin, such as short term pain relief, short term sedation and hormone release, are reversed by oxytocin antagonists and can thus be described as direct effects.

The long term effects, amounting to days-months of relief, which are obtained after repeated treatments, for 3-
10 days, preferably for 5-8 days, in intervals ranging from weeks to months, are surprising not only in a pain relieving perspective but also in a general perspective and have not previously been reported for any other drug in patients. When said effect has been obtained it can be maintained by for instance once in a week treatment. This long term effect is reversed by α₂-antagonists and potentiated by α₂-agonists.

The pharmaceutical composition containing oxytocin can be formulated for topical, iontophoretical, nasal, intrapulmonary, parenteral, such as subcutaneous, intraperitoneal or intravenous, intrathecal or intracerebroventricular administration. A preferred way of administration is intranasally. A parenteral composition is for instance a solution or emulsion for subcutaneous, intramuscular or intravenous injection. A topical composition can be a lotion, cream, ointment or gel, for instance incorporated into a plaster.

Doses to be given in topical administration can be 1-1000 μg/cm², preferably 10-100 μg/cm²; in parenteral administration 0.05-1 mg/kg; and in nasal administration 1-100 IU/d, preferably 25-50 IU/d. 1 IU or international unit corresponds to 2 μg. To children with navel colic a preferred dose might be 20-50, preferably 25-30 IU/d nasally, preferably administered 2-3 times during 1-2 hours. In i.c.v. or i.t. administration the doses are generally 1/10 to 1/1000 of the parenteral doses.

In the market there are today commercial solutions for injection and nasal sprays.

**Description of the drawings**

Figure 1 is a bar graph of the estimated pain, discomfort and fatigue, respectively, in fibromyalgia patients after nasal administration of oxytocin.

**Biological tests**

**Test 1. Clinical study on fibromyalgia patients**

In a pilot study 12 female patients (aged 42-58 years) were treated with oxytocin (Syntocinon, Sandoz), 10 IU daily for 5 days, or saline as a control in a randomized cross-over study. All patients had previously been subjected to pharma-
collogical treatment and/or physiotherapy with little or no alleviation and were during the trial not subjected to any other treatment modality. Before and after the trial the patients rated their pain, ache-discomfort and fatigue on visual analogue scales from 0 to 100, where 0 means no discomfort.

The results summarized in figure 1 show that 7 of 12 patients treated with oxytocin reported a significant, that is more than 50 %, alleviation of their symptoms, whereas in the patients treated with saline 2 of 12 patients obtained an alleviation.

These results imply that exogenous administration of oxytocin, oxytocin agonist or a drug that releases oxytocin may alleviate the symptoms of fibromyalgia.

Test 2. Clinical study on RAP children

3 children at the age of ten with a recurrent abdominal pain syndrome for at least 1 year were given a low dose of oxytocin by nasal spraying, that is 2 x 8 IU daily in the morning for 3-5 days. The oxytocin preparation used was Syntocinon nasal spray (Sandoz, 4 IU per spray dose).

A positive effect on the general condition and reduced pain could be observed. In one case the pain disappeared instantly or within minutes from the administration and the patient called the drug "the miracle drops".

The results obtained are very promising and should be sufficient to justify a continued investigation in a controlled clinical study.

Test 3. Administration of α₂-agonist to oxytocin treated rats

In order to investigate mechanisms behind the effects of oxytocin treatment on the affective component of pain clonidine - an α₂-agonist which lowers blood pressure and causes sedation - was administered (100 μg/kg s.c.) 9 days after the end of the oxytocin treatment period. At this time the significant decrease, compared to controls, had disappeared, but after the clonidine injection a significantly sedation was again observed in the oxytocin-treated rats in comparison to the saline-treated controls.
These findings suggest that repeatedly given injections of oxytocin induce a change in the central α₂-receptors. If this change is caused by an increase in the number of receptors, a change in binding to said receptors or by some other mechanism is not yet known.
CLAIMS

1. Use of a substance with oxytocin activity for the preparation of a pharmaceutical composition for the treatment or prophylaxis of affective pain syndromes of non-organic origin, such as fibromyalgia, myofascial pain syndrome, navel colic, colitis or irritable bowel syndrome, as well as of affective components associated with pain of organic origin in mammals including man.

2. Use of a substance according to Claim 1, characterized in having the following formula I:

\[
\begin{array}{c}
S \\
\text{Cys-Tyr-W-X-Asn-Cys-Pro-Y-Z-NH}_2
\end{array}
\]

wherein
W is selected from the group consisting of Ile, Cha, Val, Hoph and Phe;
X is selected from the group consisting of Gln, Ser, Thr, Cit, Daba and Arg;
Y is selected from the group consisting of Leu, Ile, Arg, Hos, Daba, Cit and Val; where Leu, Ile and Val give oxytocin analogues and Arg, Hos, Daba and Cit give vasopressin analogues; and
Z is selected from the group consisting of Gly and Ala; as well as sequences with reversed peptide bonds.

3. Use according to claim 1 or 2, characterized in that the substance is oxytocin.

4. Use according to claim 1 or 2, characterized in that the substance is mesotocin, isotocin, vasopressin or vasotocin.

5. Use according to claim 1 or 2, characterized in that the substance is selected from the group consisting of:

\[
\begin{array}{c}
\text{Cys-Tyr-Cha-Cit-Asn-Cys-Pro-Arg-Gly-NH}_2
\end{array}
\]
Cys-Tyr-Val-Thr-Asn-Cys-Pro-Leu-Gly-NH$_2$,
Cys-Tyr-Hoph-Thr-Asn-Cys-Pro-Val-Gly-NH$_2$,
Cys-Tyr-Phe-Cit-Asn-Cys-Pro-Leu-Gly-NH$_2$,
Cys-Tyr-Cha-Arg-Asn-Cys-Pro-Hos-Ala-NH$_2$,
Cys-Tyr-Val-Daba-Asn-Cys-Pro-Daba-Ala-NH$_2$,
Cys-Tyr-Hoph-Daba-Asn-Cys-Pro-Cit-Ala-NH$_2$ and
Cys-Tyr-Phe-Arg-Asn-Cys-Pro-Val-Ala-NH$_2$.

6. Use of the substance according to any of claims 1-5, for the treatment of fibromyalgia.

7. Use of the substance according to any of claims 1-5 in combination with estrogen.

8. Use of a substance according to any of claims 1-5, for the treatment of navel colic.

9. Use according to any of claims 1-8, wherein the pharmaceutical composition comprises a substance with oxytocin activity in combination with a pharmaceutically inert carrier.

10. Use according to any of claims 1-9, wherein the pharmaceutical composition is formulated for nasal, parenteral or topical administration.

11. Use according to any of claims 1-10, wherein the pharmaceutical composition is in the form of a nasal spray.

12. Method of treatment of musculoskeletal pain syndromes of non-organic origin, such as fibromyalgia, myofascial pain syndrome, navel colic, colitis or irritable bowel syndrome, as well as of affective components associated with pain of
organic origin, comprising administration of a therapeutically effective dose of a substance with oxytocin activity or an oxytocin agonist, especially oxytocin.

13. Method of treatment according to claim 12, characterized in that the substance with oxytocin activity is administrated for 3-10 days, preferably for 5-8 days, in intervals ranging from weeks to months.

14. Method according to claim 12 or 13, comprising nasal administration of 5-100, preferably 25-50 IU of substance with oxytocin activity per day.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 38/11
According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REG, CAPLUS, MEDLINE, EMBASE, WPI, USPATFULL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>ACTA PHYSIOL SCAND, Volume 144, 1992, K. Uvnäs-Moberg et al, &quot;Oxytocin increases and a specific oxytocin antagonist decreases pain threshold in male rats&quot; page 487 - page 488</td>
<td>1-14</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

- Special categories of cited documents
  - "A" document defining the general state of the art which is not considered to be of particular relevance
  - "E" earlier document but published on or after the international filing date and which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referring to a technical disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search: 14 July 1998
Date of mailing of the international search report: 16-07-1998

Name and mailing address of the ISA/Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer
Anneli Jönsson
Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1992)
INTERNATIONAL SEARCH REPORT

Box I  Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  X  Claims Nos.:

   because they relate to subject matter not required to be searched by this Authority, namely:

   Remark: Although claims 12-14 are directed to a method of treatment of the human/animal body, the search has been carried out based on the alleged effect of the compound composition.

2. ☐ Claims Nos.:

   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:

   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II  Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)